


Target Sufficiency™ by Prototypia, an Inotiv company

Precision quantification of proteins by targeted mass spectrometry



Prototypia, now a part of Inotiv, provides a targeted proteomics platform to precisely quantify drug target systems in cells, tissue models and human tissues, directly integrating protein-level pharmacology and pathology across multiple therapeutic areas, supporting multiple therapeutic modalities from discovery through clinical development.

- **Oncology drug target systems**

- Assay panels for multiprotein systems targeted by oncology therapeutics, including immune checkpoints and related immune regulators, growth factor receptor/kinase systems, cell cycle regulators, cell death regulators, hormone receptor systems, and antibody drug conjugate (ADC) targets.

- **Enabling successful gene editing therapies**

- Precise abundance measurement of editing nucleases and key host system proteins in tissues that govern both successful editing, as well as off-target effects and toxicity. This information informs dosing strategy to maximize efficacy.

- **Autoimmune disease target and tissue landscape**

- Assay panels to quantify therapeutic target abundance, along with immune cell infiltration and key protein mediators of tissue integrity and injury.

- **Ensuring effectiveness in targeted protein modulation**

- Routinely achieve measurements over 2-3 orders of magnitude in protein abundance. Simultaneously verify the presence of critical host proteins, such as ubiquitin E3 ligase proteins to which PROTACS and similar molecules are targeted. Survey cell and tissue models for preclinical development of drug candidates and prioritize tumor types for therapeutic programs.

Contact us at inotivco.com/contact/ to discuss how Target Sufficiency™ can support your study